Biocon’s consolidated profit after tax soared to Rs 660 crore for Q1 FY24, up from Rs 101 crore in the previous year, largely due to a one-time gain from its collaboration with Eris Lifesciences. Revenue was slightly higher at Rs 3,433 crore compared to Rs 3,423 crore a year earlier. Biocon remains optimistic about future growth, with new product launches and improved prospects for Syngene. The company also addressed FDA observations on its API facilities.
